203 research outputs found
Retraction Note: Infection of great apes and a zoo keeper with the same Mycobacterium tuberculosis spoligotype: Infection of great apes and a zoo keeper with the same Mycobacterium tuberculosis spoligotype (Medical Microbiology and Immunology, (2014), 203, 2, (141-144), 10.1007/s00430-013-0323-0)
No full textThe original article has been retracted by the authors because they did not obtain informed consent to publish the description of the case. The content of this article is no longer available online to protect patient confidentiality. Authors Onno W. Akkerman, Tjip S. van der Werf, Adri G. M. van der Zanden, Tony Eger agree to this retraction. Corresponding author, Onno W. Akkerman, stated on behalf of all remaining co-authors that they agree to this retraction
Author_response_v.1 – Supplemental material for Eradication of Pseudomonas aeruginosa in cystic fibrosis patients with inhalation of dry powder tobramycin
No full textSupplemental material, Author_response_v.1 for Eradication of Pseudomonas aeruginosa in cystic fibrosis patients with inhalation of dry powder tobramycin by Anne M. Akkerman-Nijland, Mina Yousofi, Bart L. Rottier, Hester Van der Vaart, Johannes G. M. Burgerhof, Henderik W. Frijlink, Daan J. Touw, Gerard H. Koppelman and Onno W. Akkerman in Therapeutic Advances in Respiratory Disease</p
Reviewer_3_v.1 – Supplemental material for Eradication of Pseudomonas aeruginosa in cystic fibrosis patients with inhalation of dry powder tobramycin
No full textSupplemental material, Reviewer_3_v.1 for Eradication of Pseudomonas aeruginosa in cystic fibrosis patients with inhalation of dry powder tobramycin by Anne M. Akkerman-Nijland, Mina Yousofi, Bart L. Rottier, Hester Van der Vaart, Johannes G. M. Burgerhof, Henderik W. Frijlink, Daan J. Touw, Gerard H. Koppelman and Onno W. Akkerman in Therapeutic Advances in Respiratory Disease</p
Reviewer_2_v.1 – Supplemental material for Eradication of Pseudomonas aeruginosa in cystic fibrosis patients with inhalation of dry powder tobramycin
No full textSupplemental material, Reviewer_2_v.1 for Eradication of Pseudomonas aeruginosa in cystic fibrosis patients with inhalation of dry powder tobramycin by Anne M. Akkerman-Nijland, Mina Yousofi, Bart L. Rottier, Hester Van der Vaart, Johannes G. M. Burgerhof, Henderik W. Frijlink, Daan J. Touw, Gerard H. Koppelman and Onno W. Akkerman in Therapeutic Advances in Respiratory Disease</p
Reviewer_1_v.1 – Supplemental material for Eradication of Pseudomonas aeruginosa in cystic fibrosis patients with inhalation of dry powder tobramycin
No full textSupplemental material, Reviewer_1_v.1 for Eradication of Pseudomonas aeruginosa in cystic fibrosis patients with inhalation of dry powder tobramycin by Anne M. Akkerman-Nijland, Mina Yousofi, Bart L. Rottier, Hester Van der Vaart, Johannes G. M. Burgerhof, Henderik W. Frijlink, Daan J. Touw, Gerard H. Koppelman and Onno W. Akkerman in Therapeutic Advances in Respiratory Disease</p
Update of drug-resistant tuberculosis treatment guidelines: A turning point
Full text linkIn December 2022 World Health Organization released a new treatment for multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) guideline. The main novelty of this update is two new recommendations (i) a 6-month treatment regimen composed of bedaquiline, pretomanid, linezolid (600 mg), and moxifloxacin (BPaLM) is recommended in place of the 9-month or longer (18-month) regimens in MDR/RR-TB patients, now including extensive pulmonary TB and extrapulmonary TB (except TB involving central nervous system, miliary TB and osteoarticular TB); (ii) the use of the 9-month all-oral regimen rather than longer (18-months) regimen is suggested in patients with MDR/RR-TB and in whom resistance to fluoroquinolones has been excluded. Longer (18-month) treatments remain a valid option in all cases in which shorter regimens cannot be implemented due to intolerance, drug-drug interactions, extensively drug-resistant tuberculosis, extensive forms of extrapulmonary TB, or previous failure. The new guidelines represent a milestone in MDR/RR-TB treatment landscape, setting the basis for a shorter, all-oral, more acceptable, equitable, and patient-centered model for MDR/RR-TB management. However, some challenges remain to be addressed to allow full implementation of the new recommendations
A systematic review on the effect of diabetes mellitus on the pharmacokinetics of TB drugs
No full textOBJECTIVES The coexistence of TB and diabetes mellitus (DM) (TB-DM) is associated with an increased risk of treatment failure, death, delayed culture conversion, and drug resistance. Because plasma concentrations may influence clinical outcomes, we evaluated the evidence on the pharmacokinetic (PK) of TB drugs in individuals with DM to guide management. METHODS We performed a systematic review and meta-analysis through searches of major databases from 1946 to 6 July 2023. PROSPERO (CRD42022323566). RESULTS Of 4,173 potentially relevant articles, we identified 16 studies assessing rifampicin (RIF) PK, 9 on isoniazid (INH), 8 on pyrazinamide (PZA), and 3 on ethambutol (EMB). Two studies reported on second-line anti-TB drugs. According to our meta-analysis, RIF time to maximum concentration (Tmax) was significantly prolonged in patients with DM compared with non-DM patients. We found no significant differences for RIF Cmax, area under the curve (AUC) 0-24 or drug concentration at 2 h (C2h), INH C2h, PZA C2h, PZA Tmax, and EMB Tmax. Although RIF C2h was slightly reduced in patients with TB-DM, this finding was not statistically significant. CONCLUSIONS This review comprehensively examines the impact of DM on the PK of TB drugs. We observed significant heterogeneity among the studies. Given the association between lower plasma concentrations and poor clinical outcomes among patients with DM, we recommend a higher dose limit to compensate for the larger body weight of patients with DM.</p
Nerium oleander L.
No full text66. Nerium oleander L., Sp. Pl.: 209. 1753 [cited in Nat. Hist. II(4): 389. 1775]. Notes. – A specimen in the Java herbarium is in L (L-898.111-57). It represents material of Plumeria rubra L. (see Nat. Hist. II(2): 178. 1774) (Fig. 2). Two leaves and an inflorescence are mounted with a mid-18th century pot, so far only known from this sheet (G. Thijsse, pers. comm. to the first author). Another specimen without provenance is present in the Thunberg herbarium (UPS-THUNB n° 6128).Published as part of Wijnands, Dirk Onno, Heniger, Johannes, Veldkamp, Jan Frederik, Fumeaux, Nicolas & Callmander, Martin W., 2017, The botanical legacy of Martinus Houttuyn (1720 - 1798) in Geneva, pp. 155-198 in Candollea 72 (1) on page 181, DOI: 10.15553/c2017v721a11, http://zenodo.org/record/572188
- …
